Arcus Biosciences, Inc. financial data

Symbol
RCUS on NYSE
Industry
Pharmaceutical Preparations
Location
3928 Point Eden Way, Hayward, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 504 % -4%
Debt-to-equity 94.7 % +93.7%
Return On Equity -45.6 % +8.86%
Return On Assets -22.4 % +4.32%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 91.5M shares +22.3%
Common Stock, Shares, Outstanding 91.5M shares +22.3%
Entity Public Float 1.07B USD -17.8%
Common Stock, Value, Issued 7K USD 0%
Weighted Average Number of Shares Outstanding, Basic 91.4M shares +22.5%
Weighted Average Number of Shares Outstanding, Diluted 91.4M shares +22.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 263M USD +119%
Research and Development Expense 440M USD +34.6%
General and Administrative Expense 121M USD +4.31%
Operating Income (Loss) -318M USD +1.55%
Nonoperating Income (Expense) 49M USD +40.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -269M USD +6.6%
Income Tax Expense (Benefit) 1M USD -80%
Net Income (Loss) Attributable to Parent -270M USD +7.85%
Earnings Per Share, Basic -3.15 USD/shares -6.38%
Earnings Per Share, Diluted -3.15 USD/shares -6.38%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 201M USD +9.24%
Assets, Current 1.13B USD +27.8%
Property, Plant and Equipment, Net 48M USD -4%
Operating Lease, Right-of-Use Asset 92M USD -8%
Other Assets, Noncurrent 75M USD -30.6%
Assets 1.25B USD +5.12%
Accounts Payable, Current 13M USD -23.5%
Employee-related Liabilities, Current 27M USD +22.7%
Accrued Liabilities, Current 20.5M USD +40.4%
Contract with Customer, Liability, Current 105M USD +1.94%
Liabilities, Current 215M USD +7.5%
Contract with Customer, Liability, Noncurrent 289M USD -11.4%
Operating Lease, Liability, Noncurrent 110M USD -5.98%
Other Liabilities, Noncurrent 136M USD -6.21%
Liabilities 695M USD +134%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1M USD
Retained Earnings (Accumulated Deficit) -1.04B USD -35.2%
Stockholders' Equity Attributable to Parent 565M USD +8.65%
Liabilities and Equity 1.25B USD +5.12%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2M USD +98%
Net Cash Provided by (Used in) Financing Activities 229M USD +22800%
Net Cash Provided by (Used in) Investing Activities -169M USD -231%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 91.5M shares +22.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 58M USD +81.3%
Deferred Tax Assets, Valuation Allowance 233M USD +55.3%
Deferred Tax Assets, Gross 253M USD +47.1%
Operating Lease, Liability 121M USD -3.97%
Payments to Acquire Property, Plant, and Equipment 4M USD +33.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -266M USD +7.32%
Lessee, Operating Lease, Liability, to be Paid 149M USD -6.29%
Property, Plant and Equipment, Gross 82M USD +41.4%
Operating Lease, Liability, Current 11M USD +22.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 17M USD +6.25%
Lessee, Operating Lease, Liability, to be Paid, Year One 17M USD +13.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 28M USD -15.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 17M USD +6.25%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 13M USD +62.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 18M USD +5.88%
Additional Paid in Capital 1.18B USD +7.84%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 77M USD +6.94%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%